Corporate Update

Allianz Malaysia Berhad

(1163 | ALLZ MK) Financial Services | Finance

FTSE4Good ESG 3 Stars

Maintain **BUY**

Revised Target Price **RM26.77**
(from RM25.69)

2QFY26 Results Review
Some Claims Pressure

Salient Points

Decent set of earnings, as forecasted.

Our Verdict

Claims pressure should continue to drag short-term earnings, particularly since ALLZ has large exposure to the vulnerable medical and motor segments. There could also be some weakness in AGIC's segment's GWP figures, due to lower TIV expectations. However, we remain optimistic on overall growth prospects and expect a GWP recovery in subsequent quarters – particularly as macroeconomic outlook remains extremely bright.

Valuations

A revised SOTP-TP of RM 26.77 *(formerly RM25.69)*

AGIC: FY27F P/BV of 1.5x *(formerly 1.4x)*

ALIM: FY27F P/CE of 0.6x

Current P/BV of 0.63x is inexpensive, trading at -1 SD below the 10-year P/BV mean of 0.76x.

The company is trading at a forward P/BV of 1.02x and has a +4.0% dividend yield.

Themes

1. ▲ AGIC to maintain its aggressive growth, capitalising on economies of scale and market-leading position. There may be short-term growth headwinds to the motor segment (due to lower TIV), but a better-than-expected macroeconomic outlook should continue to drive this segment's growth.
2. ▲ ALIM has also seen tremendous growth recovery. Like AGIC, ALIM's growth is rapidly outpacing the rest of the industry. While preferring the agency distribution channel, ALIM is making considerable headway in both the bancassurance and employee benefits segments.
3. ▲ ALIM has been managing healthcare inflation very well, with its health loss ratios showing considerable improvement from last year. Solid take-up in co-pay products should help maintain this excellent performance.
4. ► Moderate dividend yields. Unfortunately, capital constraints will likely persist as ALLZ's high growth levels put pressure on solvency.
5. ▼ Cost inflation should pressure both AGIC's and ALIM's claims ratio. The worst hit are motor and medical segments, which ALLZ is highly exposed to.

Results in a nutshell:

► **6MFY26's Core NP of RM446m was *Within/Within* our/street forecasts: *47%/47%* of full-year forecasts.**

RETURN STATISTICS	
Price @ 21 August 2026 (RM)	22.28
Expected share price return (%)	+20.2
Expected dividend yield (%)	+4.0
Expected total return (%)	**+24.2**

SHARE PRICE CHART



Price performance (%)	Absolute	Relative
1 month	7.6	6.9
3 months	5.3	3.4
12 months	26.9	15.8

INVESTMENT STATISTICS			
FYE Dec	**FY26F**	**FY27F**	**FY28F**
Core NP (RM m)	**948**	**961**	**1,027**
CNP growth (%)	(1)	1	7
Div yield (%)	**4.0**	**4.0**	**4.3**
Gross DPS (sen)	88.5	89.7	95.8
P/BV (x)	**1.1**	**1.0**	**0.9**
BVPS (RM)	20.1	21.9	23.9
ROE (%)	**14.4**	**13.3**	**13.1**
% Street CNP (%)	**100**	**98**	**100**

KEY STATISTICS	
FBM KLCI	1,736.48
Issue shares (m)	181.5
Estimated free float (%)	31.9
Market Capitalisation (RM'm)	4,090.6
52-wk price range	RM17.5 – RM23.3
3-mth average daily volume (m)	0.1
3-mth average daily value (RM'm)	1.3
Top Shareholders (%)	
Allianz SE	63.8
EPF Board	6.6
Kumpulan Wang Persaraan Diperbadan	3.2

Analyst
Samuel Woo
samuelwoo.cy@mbsb.com
03-2173 8461

► **No dividend announcement.**

▲ **6MFY26's Core net profit (NP) of RM446m up by +4%yoy.** The increase was driven by better insurance revenue, investment returns, and reinsurance expenses; this offset higher claims and insurance finance expenses.

▼ **2QFY26's Core NP of RM219m down by -4%qoq.** The decrease was driven by higher insurance expenses and insurance finance expenses, which offset lower reinsurance costs and better investment returns.

▲ **6MFY26's GWP of RM298m up by +12%yoy.** AGIC's GWP of RM2,002m up by +7%yoy, while ALIM's GWP of RM2,364m up by +16%yoy.

▼ **AGIC's 6MFY26 PBT of RM298m was down by -5%yoy.** The weakness came largely from a higher claims ratio, which offset the increase in insurance revenue and lower reinsurance expenses.

▼ **AGIC's 6MFY26 Combined ratio of 88.3% up by +0.9%yoy.** This is largely attributable to the higher claims ratio seen this quarter.

▲ **ALIM's 6MFY26 PBT of RM294m up by +14%yoy.** There were improvements in insurance revenue and investment returns, which offset higher claims and insurance finance expenses.

Forecasts unchanged. We make no changes to our earnings forecasts.
Key downside risks. *(1) High claim inflation pressure persists, (2) Poor investment gains, (3) Weaker-than-expected dividend payout.*

Maintain BUY call: Revised SOTP-TP of RM 26.77 ***(from RM25.69).*** This is to reflect an altered valuation base – we positively tweak AGIC's valuation to factor in an improving macroeconomic outlook, which bodes well for the segment's growth prospects.

(1) **For AGIC, we use a FY27F P/BV of 1.5x.** *(formerly 1.4x)*
(2) **For ALIM, we use an FY27F P/CE of 0.6x.**

FIG 1: SOTP Valuation

Companies	Equity Value (RM mil)	Equity Value basis	Multiple (X)	Valuation basis	Valuation (RM mil)
AGIC	**3,688**	FY27F P/BV	**1.5**	P/BV	**5,532**
ALIM	**6,105**	FY27F P/CE	**0.6**	P/CE	**3,663**
Total sum-of-parts					**9,195**
(÷) Diluted ALLZ Share Base (mil)					344
Fair value (RM)					**26.77**

Source: Company, MBSBR

FIG 2: Quarterly results

FYE Dec (RM m)	2Q FY26	1Q FY26	2Q FY25	Yoy (%)	Qoq (%)	1H FY26	1H FY25	Yoy (%)
Insurance revenue	1,630	1,631	1,520	7	-0	3,261	3,049	7
Insurance expenses	(1,414)	(1,241)	(1,237)	14	14	(2,656)	(2,356)	13
Claims	*(1,020)*	*(856)*	*(867)*	18	19	*(1,877)*	*(1,641)*	14
Acquisitions & Admin exp	*(397)*	*(383)*	*(371)*	7	4	*(780)*	*(710)*	10
Onerous contracts	*3*	*(2)*	*1*	361	-238	*1*	*(5)*	-116
Reinsurance	16	(69)	(69)	-123	-123	(53)	(163)	-67
Insurance service result	**231**	**321**	**214**	8	-28	**552**	**530**	4
Investment return	516	115	427	21	350	631	314	101
Net insurance finance exp	(390)	(105)	(281)	39	272	(494)	(155)	219
Net ins & inv result	**357**	**151**	**146**	144	137	**689**	**689**	0
Other income/OPEX	(46)	(47)	(76)	-40	-2	(93)	(121)	-23
Associates	-	-	-	n.m.	n.m.	-	-	n.m.
PBT	**311**	**284**	**284**	**10**	**9**	**595**	**567**	**5**
Tax	(93)	(57)	(69)	34	63	(149)	(138)	8
NCI	-	-	-	n.m.	n.m.	-	-	n.m.
Reported NP	**219**	**227**	**215**	**2**	**-4**	**446**	**429**	**4**
Core NP	**219**	**227**	**215**	**2**	**-4**	**446**	**429**	**4**
Gross DPS (sen)	**-**	**35.5**	**-**	**n.m.**	**n.m.**	**35.5**	**-**	**n.m.**
Core EPS (sen)	63.2	65.7	62.2	1	-4	128.8	124.5	4
GWP	**2,080**	**2,285**	**1,905**	**9**	**-9**	**4,365**	**3,914**	**12**
General	938	1,064	898	4	-12	2,002	1,876	7
Life	1,143	1,221	1,007	13	-6	2,364	2,038	16

Ratios (%)	2Q FY26	1Q FY26	2Q FY25	Yoy (ppts)	Qoq (ppts)	1H FY26	1H FY25	Yoy (ppts)
ROE (Ann.)	**13.3**	**14.0**	**14.1**	**-0.7**	**-0.7**	**13.6**	**14.1**	**-0.5**
Underwriting margin	**14.2**	**19.7**	**14.1**	**0.1**	**-5.5**	**16.9**	**17.4**	**-0.4**
Combined	**88.7**	**83.2**	**91.0**	**-2.3**	**5.5**	**85.9**	**86.6**	**-0.7**
Claims	62.4	52.6	57.0	5.4	9.8	57.5	54.0	3.5
Reinsurance	(1.0)	4.2	4.5	-5.5	-5.2	1.6	5.3	-3.7
Expense	27.2	26.4	29.4	-2.2	0.8	26.8	27.3	-0.5

Source: Company, MBSBR

FIG 3: Quarterly results (General)

FYE Dec (RM m)	2Q FY26	1Q FY26	2Q FY25	Yoy (%)	Qoq (%)	1H FY26	1H FY25	Yoy (%)
Insurance revenue	926	918	886	5	1	1,844	1,748	5
Insurance expenses	(832)	(720)	(710)	17	16	(1,552)	(1,361)	14
Claims	*(611)*	*(505)*	*(504)*	*21*	*21*	*(1,116)*	*(968)*	*15*
Acquisitions & Admin exp	*(221)*	*(214)*	*(205)*	*8*	*3*	*(436)*	*(392)*	*11*
Onerous contracts	*1*	*(2)*	*(0)*	*<-500*	*-144*	*(1)*	*(2)*	*-42*
Reinsurance	29	(65)	(50)	-158	-144	(36)	(128)	-72
Insurance service result	**123**	**133**	**127**	-3	-8	**256**	**259**	-1
Investment return	70	70	77	-9	1	140	144	-3
Net insurance finance exp	(29)	(29)	(26)	12	1	(58)	(52)	12
Net ins & inv result	**164**	**174**	**178**	-8	-6	**338**	**351**	-4
Other income	1	0	0	n.m.	n.m.	1	1	n.m.
Other OPEX	(21)	(20)	(25)	-17	4	(41)	(39)	5
PBT	**144**	**154**	**153**	-6	-7	**298**	**313**	-5

Ratios (%)	2Q FY26	1Q FY26	2Q FY25	Yoy (ppts)	Qoq (ppts)	1H FY26	1H FY25	Yoy (ppts)
Underwriting margin	**13.2**	**14.5**	**14.3**	**-1.1**	**-1.2**	**13.9**	**14.8**	**-0.9**
Combined	**88.9**	**87.7**	**88.5**	**0.4**	**1.3**	**88.3**	**87.4**	**0.9**
Claims	65.9	55.1	56.9	9.0	10.8	60.6	55.4	5.1
Reinsurance	(3.1)	7.1	5.6	-8.7	-10.2	2.0	7.3	-5.4
Expense	26.1	25.5	26.0	0.1	0.6	25.8	24.6	1.2

Source: Company, MBSBR


FIG 4: Quarterly results (Life)

FYE Dec (RM m)	2Q FY26	1Q FY26	2Q FY25	Yoy (%)	Qoq (%)	1H FY26	1H FY25	Yoy (%)
Insurance revenue	704	713	634	11	-1	1,417	1,301	9
Insurance expenses	(582)	(521)	(528)	10	12	(1,103)	(995)	11
Claims	*(409)*	*(351)*	*(363)*	*13*	*16*	*(760)*	*(674)*	*13*
Acquisitions & Admin exp	*(175)*	*(169)*	*(166)*	*6*	*4*	*(344)*	*(318)*	*8*
Onerous contracts	*2*	*(0)*	*1*	*211*	*<-500*	*2*	*(3)*	*-152*
Reinsurance	(13)	(4)	(19)	-32	238	(17)	(35)	-51
Insurance service result	**109**	**189**	**87**	24	-42	**297**	**271**	10
Investment return	440	40	345	28	>500	480	161	199
Net insurance finance exp	(361)	(76)	(255)	41	375	(437)	(103)	322
Net ins & inv result	**188**	**153**	**177**	6	23	**341**	**329**	4
Other income	0	0	0	n.m.	n.m.	0	0	n.m.
Other OPEX	(22)	(25)	(47)	-53	-11	(47)	(72)	-35
PBT	**166**	**128**	**130**	**28**	**30**	**294**	**257**	**14**
ANP	**225**	**263**	**235**	-4	-15	**488**	**448**	9

Ratios (%)	2Q FY26	1Q FY26	2Q FY25	Yoy (ppts)	Qoq (ppts)	1H FY26	1H FY25	Yoy (ppts)
Block persistency	**80.1**	**83.0**	**88.9**	**-8.8**	**-2.9**	**10.8**	**11.4**	**-0.6**
Underwriting margin	**15.4**	**26.5**	**13.8**	**1.6**	**-11.0**	**21.0**	**20.9**	**0.1**
Combined (Estimates)	**87.7**	**77.0**	**93.6**	**-5.9**	**10.7**	**82.3**	**84.6**	**-2.3**


Source: Company, MBSBR

FIG 5: QoQ P/L walk (Quarterly)




Source: Company, MBSBR

FIG 6: YoY P/L walk (Quarterly)




Source: Company, MBSBR

FIG 7: YoY P/L walk (Cumulative)




Source: Company, MBSBR

FIG 8: QoQ P/L walk (Multiple Quarters)




Source: Company, MBSBR

FIG 9: General Segment YoY PBT walk (Cumulative)



Source: Company, MBSBR

FIG 10: Life Segment YoY PBT walk (Cumulative)




Source: Company, MBSBR


FIG 11: Quarterly Performance by Segment

1. General — Overall: ► Moderate | Qtr: -7%qoq, -6%yoy | Cumulative: -5%yoy


PBT (RM m)



Combined Ratio (%)




GWP (RM m)




Commentary: Even with the notable uptick in claims ratio this quarter, PBT was well preserved, attributable to slightly stronger insurance revenue and positive reinsurance outflow.

2. Life — Overall: ▲Strong | Qtr: +30%qoq, +28%yoy | Cumulative: +14%yoy


PBT (RM m)




Block Persistency Ratio (%)




GWP (RM m)



Expense Ratio (%)



Annualised New Premium (RM m)




Commentary: An exceptional quarter, driven by strong insurance revenue and investment returns, which offset higher claims and insurance finance expenses.

Source: Company, MBSBR


SEGMENTAL BREAKDOWN

FIG 12: GWP by Segment (Quarterly)




Source: Company, MBSBR

FIG 13: PBT by Segment, with Group Core NP (Quarterly)




Source: Company, MBSBR

FIG 14: Insurance Service Result by Segment (Quarterly)




Source: Company, MBSBR

FIG 15: Insurance Revenue by Segment (Quarterly)




Source: Company, MBSBR

FIG 16: Insurance & Reinsurance Expenses by Segment (Quarterly)




Source: Company, MBSBR

FIG 17: Combined Ratio by Segment (Quarterly)




Source: Company, MBSBR

FIG 18: Claims Ratio by Segment (Quarterly)




Source: Company, MBSBR

FIG 19: Reinsurance Ratio by Segment (Quarterly)



Source: Company, MBSBR

FIG 20: Expense Ratio by Segment (Quarterly)



Source: Company, MBSBR

FINANCIAL SUMMARY

INCOME STATEMENT

FYE Dec (RM m)	FY24	FY25	FY26F	FY27F	FY28F
Insurance revenue	5,651	6,237	6,821	7,462	8,163
Insurance service expenses	(4,553)	(4,989)	(5,554)	(6,075)	(6,646)
Reinsurance expense	(280)	(279)	(319)	(351)	(386)
Insurance service result	**818**	**969**	**948**	**1,036**	**1,130**
Investment return	1,577	1,058	1,129	1,127	1,152
Net finance result	(1,177)	(660)	(676)	(708)	(742)
Total ins, inv & financial result	**1,218**	**1,367**	**1,401**	**1,455**	**1,540**
Other income	5	26	26	26	26
Other OPEX	(217)	(228)	(228)	(228)	(228)
Associates	-	-	-	-	-
PBT	**1,005**	**1,166**	**1,200**	**1,253**	**1,339**
Tax	(235)	(207)	(252)	(292)	(312)
NCI	-	-	-	-	-
Reported NP	**771**	**959**	**948**	**961**	**1,027**
Core NP	**771**	**959**	**948**	**961**	**1,027**

BALANCE SHEET

FYE Dec (RM m)	FY24	FY25	FY26F	FY27F	FY28F
Cash & ST funds	2,027	1,788	1,788	1,788	1,788
Investment securities	25,121	27,128	29,298	31,642	34,173
Other assets	1,341	1,579	1,571	1,745	1,938
Total assets	**28,488**	**30,495**	**32,657**	**35,175**	**37,899**
Insurance contracts	21,220	22,371	23,489	24,664	25,897
Other liabilities	1,440	1,837	2,265	2,984	3,809
Total liabilities	**22,660**	**24,208**	**25,755**	**27,648**	**29,706**
Share capital	241	256	256	256	256
Reserves	5,057	5,516	6,132	6,756	7,422
Total equity	**5,828**	**6,287**	**6,903**	**7,527**	**8,193**
Total L&E	**28,488**	**30,495**	**32,657**	**35,175**	**37,899**

Source: Company, MBSBR

FINANCIAL RATIOS

FYE Dec (RM m)	FY24	FY25	FY26F	FY27F	FY28F
Profitability (%)					
ROE	14.1	15.8	14.4	13.3	13.1
ROA	3.0	4.0	3.0	2.8	2.8
Combined ratio (%)	**85.5**	**84.5**	**86.1**	**86.1**	**86.2**
Claims	56.4	55.9	55.7	55.7	55.7
Expenses	24.2	24.1	25.7	25.7	25.7
Reinsurance	5.0	4.5	4.7	4.7	4.7
Growth (%)					
Insurance revenue	14.4	10.4	9.4	9.4	9.4
Insurance expense	16.9	9.6	11.3	9.4	9.4
Insurance service result	0.2	18.5	-2.1	9.2	9.2
Net ins & investment result	8.2	12.2	2.5	3.8	5.9
PBT	5.1	15.9	2.9	4.4	6.8
Core NP	5.4	24.4	-1.1	1.4	6.8
Valuation metrics					
Core EPS (sen)	224.4	279.1	276.0	279.9	298.9
Gross DPS (sen)	89.5	89.5	88.5	89.7	95.8
Div payout (%)	40	32	32	32	32
BVPS (RM)	17.0	18.3	20.1	21.9	23.9
Core P/E (x)	9.9	8.0	8.1	8.0	7.5
Div yield (%)	**4.0**	**4.0**	**4.0**	**4.0**	**4.3**
P/BV (x)	1.3	1.2	1.1	1.0	0.9

MBSB RESEARCH is part of MBSB Investment Bank Berhad 197501002077 (24878-X)

(Bank Pelaburan) (A Participating Organisation of Bursa Malaysia Securities Berhad)

DISCLOSURES AND DISCLAIMER

This report is prepared by MBSB Investment Bank Berhad (Company Registration No.: 197501002077 (23878-X)) and is for distribution only to the intended readers and under such circumstances as may be permitted by applicable law. Readers should be fully aware that this report is provided solely for informational purposes and does not constitute a Shariah advice nor constitute an investment recommendation or basis for any credit or other evaluation in any manner whatsoever.

The opinions and analyses contained in this report are based on information obtained or derived from sources that MBSB Investment Bank Berhad believes to be reliable. Any forward-looking statements in this report speak only as of the date of such statements. However, MBSB Investment Bank Berhad makes no representation or warranty, expressed or implied, as to the accuracy, completeness, or reliability of such information, and it should not be relied upon as such.

While the information presented in this report may include references to Shariah -compliant and non-compliant securities or other financial instruments, this report is not, and should not be construed as, an offer to buy or sell any securities or other financial instruments or to promote or endorse any specific investment. Investors are strongly advised to conduct their own due diligence and to consult licensed Shariah or financial advisors before making any investment decisions. Any action taken based on this report is at the sole discretion and risk of the investor.

The analyses in this report are based on numerous assumptions, and different assumptions could yield different results. All opinions and estimates in this report are subject to change without notice.

The research analysts will initiate, update, and cease coverage solely at the discretion of MBSB Investment Bank Berhad.

The directors, employees, and representatives of MBSB Investment Bank Berhad and MBSB Berhad may have interests in any of the securities mentioned and may benefit from the information contained herein. Members of MBSB Berhad and their affiliates may provide services to any company or its affiliates whose securities are mentioned in this report.

This report shall not be reproduced, distributed, or published in any form or for any purpose without the prior written consent of MBSB Investment Bank Berhad.

MBSB INVESTMENT BANK: GUIDE TO RECOMMENDATIONS

STOCK RECOMMENDATIONS

BUY	Total return is expected to be >10% over the next 12 months.
TRADING BUY	The stock price is expected to rise by >10% within 3 months after a Trading Buy rating has been assigned due to positive news flow.
NEUTRAL	Total return is expected to be between -10% and +10% over the next 12 months.
SELL	Total return is expected to be <-10% over the next 12 months.
TRADING SELL	The stock price is expected to fall by >10% within 3 months after a Trading Sell rating has been assigned due to negative news flow.

SECTOR RECOMMENDATIONS

POSITIVE	The sector is expected to outperform the overall market over the next 12 months.
NEUTRAL	The sector is to perform in line with the overall market over the next 12 months.
NEGATIVE	The sector is expected to underperform the overall market over the next 12 months.

ESG RECOMMENDATIONS* - source Bursa Malaysia and FTSE Russell

☆☆☆☆	Top 25% by ESG Ratings amongst PLCs in FBM EMAS that have been assessed by FTSE Russell
☆☆☆	Top 26-50% by ESG Ratings amongst PLCs in FBM EMAS that have been assessed by FTSE Russell
☆☆	Top 51%- 75% by ESG Ratings amongst PLCs in FBM EMAS that have been assessed by FTSE Russell
☆	Bottom 25% by ESG Ratings amongst PLCs in FBM EMAS that have been assessed by FTSE Russell

* ESG Ratings of PLCs in FBM EMAS that have been assessed by FTSE Russell in accordance with FTSE Russell ESG Ratings Methodology